Show
Sort by
-
Is a single driver gene mutation sufficient for monitoring early response in advanced colorectal cancer
-
- Journal Article
- A1
- open access
Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer : a post hoc analysis of two non-randomized phase II trials
-
- Journal Article
- A2
- open access
Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor
-
Circulating tumor DNA detects early response to regorafenib in advanced colorectal cancer
-
High levels of cell-free DNA (cfDNA) at baseline (BL) and increase of at least one mutation at day 14 (D14) as independent prognostic biomarkers for patients (pts) with advanced colorectal cancer (aCRC) under regorafenib
-
Baseline cell-free DNA (cfDNA) and metabolic tumor volume (MTV) independently predict outcome in metastatic chemorefractory colorectal cancer (mCRC)
-
Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study
-
Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy
-
Locoregional and radioisotopic targeted treatment of neuroendocrine tumours
-
Diagnostic pitfalls in digestive neuroendocrine tumours